Theralase Technologies Inc. V.TLT

Alternate Symbol(s): V.TLT.W | TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc.

Bullboard Posts

Comment by Claridgeon Oct 30, 2019 11:47pm

112 Views

Post# 30289965

RE:RE:On the verge of exciting results

FRIDAY 15th of November

9h00-11h00 : SESSION 4 – METAL COMPLEXES AGAINST CANCER IN PRECLINICAL TRIAL AND PHASE II CLINICAL TRIAL
- A ferrocenyl compounds in preclinical phase against cancer (Grard Jaouen).
- A ruthenium complex beginning clinical phase II trials and Gallium complex against bone malignancies and bone disorders also beginning phase II clinical trials (Bernhard Keppler).

11h-11h30 : COFFEE BREAK

11h30-12h30 : SESSION 5 – METAL COMPLEXES AGAINST CANCER IN PHASE I CLINICAL TRIAL
- A ruthenium complex as a Photodynamic Therapy (PDT) agent in phase I clinical trial against cancer (Sherri McFarland).

12h30-14h00 : LUNCH

14h00-15h00 : SESSION 6 – METAL COMPLEXES AGAINST CANCER IN PRECLINICAL TRIAL
- A ruthenium complex in preclinical phase against cancer (Paul Dyson).

15h00-16h30 : SESSION 7 – DEBATE ON THE FUTURE OF METAL-BASED DRUG CANDIDATES
- What to do to raise the interest of industry with metal-based drug candidates? (Sherri McFarland, Christophe Biot, Roger Alberto, Paul Dyson, Grard Jaouen, Bernhard Keppler, Gilles Gasser)

___________________________

goldn1 - (10/30/2019 10:09:35 PM)
RE:On the verge of exciting results

ego: Not sure if you mentioned this, but it looks like our girl Sherri with be making a presentation regarding ru in Paris in a few weeks. If this has already been posted, apologies in advance as I have been out of pocket... https://metalsinmedicine.chimieparistech.psl.eu/programme/

Bullboard Posts

Maximizing savings: Exploring 5 cash-back and promo deal apps